Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Trial Profile

Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Clopidogrel (Primary) ; Ticagrelor
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Acronyms SWAP-4
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
    • 15 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 22 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top